This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Peripheral Effects of Endotoxin on Insulin Resistance

This study has been completed.
Information provided by:
Aarhus University Hospital Identifier:
First received: June 22, 2009
Last updated: October 1, 2010
Last verified: October 2010
The aim of the study is to isolate the direct effects of endotoxin on glucose, lipid and protein metabolism. Eight healthy volunteers are enrolled. The hypothesis is that endotoxin will induce insulin resistance, lypolysis and proteolysis acutely.

Condition Intervention
Healthy Biological: USP endotoxin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: The Effect of Regional Inflammation on Metabolism and Insulin Sensitivity in the Lower Extremity.

Resource links provided by NLM:

Further study details as provided by Aarhus University Hospital:

Primary Outcome Measures:
  • glucose concentration [ Time Frame: 360 minutes observation ]

Secondary Outcome Measures:
  • Regional arteriovenous amino-acid balance [ Time Frame: measured at t=180 and 360 minutes ]
  • Intra-cellular insulin signaling [ Time Frame: measured at t=0, 120, and, 210 minutes ]
  • Regional arteriovenous lipid balance [ Time Frame: measured at t=180 and 360 minutes ]

Estimated Enrollment: 8
Study Start Date: June 2009
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Endotoxin Biological: USP endotoxin
Continuous intra-arterial infusion
Other Name: USP Endotoxin, LOT: G3E069


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Normal health
  2. 22 < BMI < 28
  3. Written Informed Concent

Exclusion Criteria:

  1. Any disease
  2. Any use of medication
  3. Recent immobilization of a lower extremity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00929136

The Medical Research Laboratories, Dept. M, Aarhus University Hospital
Aarhus, Denmark, 8000
Sponsors and Collaborators
Aarhus University Hospital
Principal Investigator: Mads Buhl, M.D. Medical Department M (Endocrinology and Diabetes), Århus University Hospital, Denmark
Study Director: Niels Moller, M.D., professor, Dmsc Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital, Denmark
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Niels Moller M.D. and Mads Buhl, M.D, University of Aarhus Identifier: NCT00929136     History of Changes
Other Study ID Numbers: Aarhus University Hospital
Study First Received: June 22, 2009
Last Updated: October 1, 2010

Keywords provided by Aarhus University Hospital:
Insulin resistance
Intracellular Insulin Signaling
Regional effects of inflammation/endotoxin

Additional relevant MeSH terms:
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on August 21, 2017